- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02859064
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Study Overview
Status
Intervention / Treatment
Detailed Description
This is an open-label, prospective, multi-center Phase II study for patients with metastatic well-to-moderately differentiated neuroendocrine tumors, including typical carcinoid and pancreatic neuroendocrine tumors, who are candidates for liver-directed radioembolization.
Lanreotide (Somatuline® Depot) Injection, is FDA-approved for treating unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroentero-pancreatic neuro-endocrine tumors (GEP-NETs) to improve progression-free survival. Radioembolization with yttrium-90 microspheres (SIR-Spheres® therapy) is FDA-approved for treating liver metastases from colorectal cancer. While each of these individual treatments has had promising results, investigators hypothesize that treatment for patients with NETs can be optimized by co-administration of both therapies. Patients will receive treatment with lanreotide (120 mg subcutaneously every 28 days) in combination with SIR-Spheres therapy. The dose and treatment day of SIR-Spheres will be determined by the treating radiation oncologist. Patients who are currently receiving or have previously received lanreotide are eligible, and treatment with lanreotide can continue monthly until disease progression or unacceptable toxicity. Up to 25 patients are planned for enrollment to be conducted at approximately 5 investigational sites in the U.S.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Rocky Mountain Cancer Center
-
-
Missouri
-
Kansas City, Missouri, United States, 64132
- Research Medical Center/HCA Midwest
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology PLLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Metastatic well-to-moderately differentiated (or low-grade) neuroendocrine carcinoma, including typical carcinoid or pancreatic islet cell carcinoma.
- Computerized tomography (CT) scan evidence of liver metastases which are not treatable by surgical resection or local ablation with curative intent at the time of study entry. If a CT scan is not possible, then an MRI may be used.
- Patients who are currently receiving or have previously received lanreotide or another somatostatin analogue are eligible. Previous treatment with lanreotide or another somatostatin analogue is not required for study entry.
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
- Adequate hematologic, hepatic and renal function.
- Male patients with female partners of childbearing potential and women patients of childbearing potential are required to use two forms of acceptable contraception, including one barrier method, during their participation in the study and for 3 months (90 days) following last dose of study drug(s). Male patients must also refrain from donating sperm during their participation in the study and for 3 months after last dose of study drug(s).
- Life expectancy ≥ 3 months.
- Willingness and ability to comply with study and follow-up procedures.
- Ability to understand the nature of this study and give written informed consent.
Exclusion Criteria:
- Anti-cancer therapy with the exception of lanreotide or another somatostatin analogue within 21 days or 5 half-lives (whichever is shorter) of starting study treatment.
- Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤28 days or limited field radiation for palliation ≤7 days prior to Cycle 1 Day 1 or has not recovered from side effects of such therapy.
- Major surgical procedures ≤28 days of beginning study drug, or minor surgical procedures ≤7 days. No waiting required following port-a-cath placement.
- Previously untreated brain metastases. Patients who have received radiation or surgery for brain metastases are eligible if therapy was completed at least 2 weeks prior to study entry and there is no evidence of central nervous system disease progression, mild neurologic symptoms, and no requirement for chronic corticosteroid therapy.
- Clinically significant ascites, cirrhosis, portal hypertension, or thrombosis as determined by clinical or radiologic assessment.
- Pregnant or lactating.
- Acute or chronic liver, renal, or pancreas disease.
Any of the following cardiac diseases currently or within the last 6 months:
- Left Ventricular Ejection Fraction (LVEF) <45% as determined by Multiple Gated Acquisition (MUGA) scan or echocardiogram (ECHO)
- QTc interval >480 ms on screening electrocardiogram (ECG)
- Unstable angina pectoris
- Congestive heart failure (New York Heart Association (NYHA) ≥ Grade 2
- Acute myocardial infarction
- Conduction abnormality not controlled with pacemaker or medication
- Significant ventricular or supraventricular arrhythmias (patients with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible)
- Valvular disease with significant compromise in cardiac function
- Inadequately controlled hypertension (i.e., systolic blood pressure [SBP] greater than 180 mmHg or diastolic blood pressure (DBP) greater than100 mmHg) (patients with values above these levels must have their blood pressure (BP) controlled with medication prior to starting treatment).
- Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular weight heparin is allowed.
- Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
- Known diagnosis of human immunodeficiency virus, hepatitis B or hepatitis C. Lab test results will be confirmed by the treating physician prior to study enrollment using patient's records not more than 1 year old.
- Presence of other active cancers, or history of treatment for invasive cancer ≤5 years. Patients with Stage I cancer who have received definitive local treatment and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e., non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lanreotide/Y-90 microspheres
Lanreotide: 120 mg by subcutaneous injection (SQ) on Day 1 of every cycle (every 28 days) in combination with SIR-Spheres therapy. Y-90 (Yttrium-90) microspheres [SIR-Spheres therapy]: dose and treatment day to be determined by treating radiation oncologist. |
Administered every 28 days irrespective of when SIR-Spheres is administered.
No waiting or adjusting of schedule is required.
Lanreotide treatment may continue monthly until disease progression or unacceptable toxicity occurs.
Other Names:
To be administered by injection through a trans-femoral catheter into the hepatic artery.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability
Time Frame: From the day of the first dose to 30 days after the last dose of study medication, up to 52 months
|
Treatment-emergent Adverse Events were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03.
|
From the day of the first dose to 30 days after the last dose of study medication, up to 52 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: At 12 weeks post-treatment with SIR-Spheres then every 8 weeks, up to 52 months
|
Percentage of patients with confirmed complete or partial response (CR or PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1),: Complete Response (CR): Disappearance of all target and non-target lesions; Partial Response (PR): >=30% decrease in the sum of the diameters of target lesions; Overall Response (OR) = CR + PR.
|
At 12 weeks post-treatment with SIR-Spheres then every 8 weeks, up to 52 months
|
Disease Control Rate
Time Frame: At 12 weeks post-treatment with SIR-Spheres then every 8 weeks, up to 52 months.
|
Percentage of patients with CR, PR or stable disease (SD) according to RECIST v1.1.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1),: Complete Response (CR): Disappearance of all target and non-target lesions; Partial Response (PR): >=30% decrease in the sum of the diameters of target lesions; Stable Disease: Meeting neither criteria for PR or Progression (PD= greater than 20% increase in the sum of diameters of target lesions, or an unequivocal increase in a non-target lesion, or the appearance of new lesions).
Disease Control Rate (DCR) = CR + PR + SD.
|
At 12 weeks post-treatment with SIR-Spheres then every 8 weeks, up to 52 months.
|
Progression Free Survival
Time Frame: At 12 weeks post-treatment with SIR-Spheres then every 8 weeks, up to 52 months
|
The time from Day 1 of study drug administration to disease progression as defined by RECIST v1.1, or death on study.
Per RECIST V1.1 criteria, progression is defined as a greater than 20% increase in the sum of diameters of target lesions, or an unequivocal increase in a non-target lesion, or the appearance of new lesions.
|
At 12 weeks post-treatment with SIR-Spheres then every 8 weeks, up to 52 months
|
Overall Survival
Time Frame: At 12 weeks post-treatment with SIR-Spheres then every 8 weeks, up to 52 months
|
The time from Day 1 of study drug administration until death from any cause.
|
At 12 weeks post-treatment with SIR-Spheres then every 8 weeks, up to 52 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: David Spigel, M.D., SCRI Development Innovations, LLC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Neuroendocrine Tumors
- Carcinoid Tumor
- Antineoplastic Agents
- Lanreotide
Other Study ID Numbers
- SCRI GI 221
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Neoplasms
-
Peking University Cancer Hospital & InstituteActive, not recruitingGastrointestinal CancerChina
-
Novartis PharmaceuticalsActive, not recruitingNeoplasms, Gastrointestinal TractChina, Canada, Estonia, Italy, Turkey, Argentina, Israel, Netherlands, Poland, Russian Federation, Thailand, Brazil, Chile, Hong Kong, Hungary, India, Mexico, Peru, Taiwan, Ukraine, United States, Korea, Republic of, Puerto Rico
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruiting
-
Sun Yat-sen UniversityUnknownGastrointestinal CancersChina
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompleted
-
Brigette MaRecruiting
-
Istituto Clinico HumanitasRecruitingGastrointestinal Subepithelial TumorsItaly
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC Utrecht; University of Cambridge; IRCCS Fondazione Stella MarisRecruitingGastrointestinal Cancer MetastaticNetherlands, United Kingdom, Italy
-
Sumitomo Pharma America, Inc.CompletedAdvanced Gastrointestinal CancerUnited States, Canada
-
University Medical Center GroningenCompleted
Clinical Trials on Lanreotide
-
University Hospital, GhentCompleted
-
IpsenCompleted
-
IpsenCompletedCarcinoma | Peritoneal Neoplasms | Intestinal ObstructionFrance, Netherlands, Belgium
-
Radboud University Medical CenterIpsenUnknownLiver Diseases | Hepatomegaly | Polycystic Liver Disease | Polycystic Kidney | Autosomal DominantNetherlands, Belgium
-
IpsenCompleted
-
Asan Medical CenterSamsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaboratorsRecruitingNeuroendocrine TumorsKorea, Republic of
-
Federation Francophone de Cancerologie DigestiveTerminatedMetastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine TumoursFrance, Belgium, Germany, United Kingdom
-
University Hospital, GhentIpsenCompleted
-
IpsenCompletedGastroenteropancreatic Neuroendocrine TumorChina
-
IpsenCompletedAcromegalyFrance, Switzerland